Volume 5.33 | Sep 2

Hematopoiesis News 5.33 September 2, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Conversion of Human Fibroblasts into Monocyte-Like Progenitor Cells
Researchers report on the establishment of a novel methodology allowing for the conversion of human fibroblasts into hematopoietic progenitor-like cells with macrophage differentiation potential. [Stem Cells] Abstract
NEW MesenPure™ Highly Enriched Mouse MSC Cultures Without the Wait FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
Down Syndrome-Associated Hematopoiesis Abnormalities Created by Chromosome Transfer and Genome Editing Technologies
In vitro hematopoietic differentiation assays showed that the N-terminally truncated GATA1 (GATA1s) mutation blocked erythropoiesis irrespective of an extra chromosome 21, while trisomy 21 (Ts21) and the GATA1s mutation independently perturbed megakaryopoiesis and the combination of Ts21 and the GATA1s mutation synergistically contributed to an aberrant accumulation of skewed megakaryocytes. [Sci Rep] Full Article

Expansion of Human and Murine Hematopoietic Stem and Progenitor Cells Ex Vivo without Genetic Modification Using MYC and Bcl-2 Fusion Proteins
Researchers describe a novel approach to expand a cytokine-dependent hematopoietic stem and progenitor cell (HSPC) population ex vivo by culturing primary adult human or murine HSPCs with fusion proteins including the protein transduction domain of the HIV-1 transactivation protein and either MYC or Bcl-2. [PLoS One]
Full Article

Angiopoietin-Like Protein 3 Promotes Preservation of Stemness during Ex Vivo Expansion of Murine Hematopoietic Stem Cells
To test the ability to expand hematopoietic stem cells in vitro prior to transplantation, two growth factor cocktails containing stem cell factor, thrombopoietin, fms-related tyrosine kinase-3 ligand or stem cell factor, thrombopoietin, insulin-like growth factor-2, fibroblast growth factor-1 either with or without the addition of angiopoietin-like protein-3 were used. [PLoS One] Full Article

Resveratrol Increases the Bone Marrow Hematopoietic Stem and Progenitor Cell Capacity
Scientists show that a three-week treatment of resveratrol increases the frequency and total numbers of normal bone marrow hematopoietic stem cells without any impact on their competitive repopulation capacity. [Am J Hematol] Abstract

Ability of Circulating Human Hematopoietic Lineage Negative Cells to Support Hematopoiesis
Investigators developed a novel mouse model and analyzed whether circulating human peripheral hematopoietic lineage negative/AP+ cells support hematopoiesis in vivo. [J Cell Biochem] Abstract

CLINICAL RESEARCH

Anti-CD22 90Y-Epratuzumab Tetraxetan Combined with Anti-CD20 Veltuzumab: A Phase I Study in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin Lymphoma
A lingering criticism of radioimmunotherapy in non-Hodgkin lymphoma is the use of cold anti-CD20 antibody along with the radiolabelled anti-CD20 antibody. Investigators instead combined radioimmunotherapy with immunotherapy targeting different B-cell antigens. [Haematologica] Abstract | Full Article

Haploidentical Hematopoietic Stem Cell Transplantation in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: No Difference in the High- and Low-Risk Groups
Investigators evaluated the outcomes of haploidentical hematopoietic stem cell transplantation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission patients. [Int J Cancer] Abstract

Lower Dose of Antithymocyte Globulin (ATG) Does Not Increase Graft-vs-Host Disease (GvHD) in Patients Undergoing Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (allo HSCT)
The appropriate dose of ATG been utilized in RIC allo HSCT is yet unknown. Researchers retrospectively compared patients who received 7.5 mg/kg (R-ATG) and 6 mg/kg (r-ATG). The cumulative incidences of acute GvHD (aGVHD) grade II-IV at 180 days were 46% and 41% and aGvHD grade III-IV were 11% and 18% in r-ATG and R-ATG, respectively. [Leuk Lymphoma] Abstract

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now.
 
REVIEWS
Bone Marrow-Derived Stem Cells and Strategies for Treatment of Nervous System Disorders: Many Protocols, and Many Results
This review offers a compendium of the methodologies aimed at providing a guide for researchers who are working in the field of bone marrow transplantation in the central nervous system. [Neuroscientist] Abstract

Bedside to Bench in Juvenile Myelomonocytic Leukemia: Insights into Leukemogenesis from a Rare Pediatric Leukemia
Juvenile myelomonocytic leukemia is a typically aggressive myeloid neoplasm of childhood that is clinically characterized by overproduction of monocytic cells that can infiltrate organs, including the spleen, liver, gastrointestinal tract, and lung. This review emphasizes recent advances in the field including mapping of the genomic and epigenome landscape, insights from new and existing disease models, targeted therapeutics, and future directions. [Blood] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Cell Culture World Congress Asia 2014
 
INDUSTRY NEWS
GSK Receives FDA Approval of an Additional Promacta® (Eltrombopag) Indication for Use in Patients with Severe Aplastic Anemia (SAA) Who Have Had an Insufficient Response to Immunosuppressive Therapy (IST)
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the once-daily use of Promacta® in patients with SAA who have had an insufficient response to IST. [GlaxoSmithKline plc] Press Release

Boston Strategics Corporation Initiates a Phase I Clinical Trial of the Anti-Cancer Agent “FF-10501″ for FUJIFILM in Patients with Advanced Hematologic Malignancies
Boston Strategics Corporation, a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc., has begun a Phase I clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies such as relapsed or refractory high-risk myelodysplastic syndromes. [Boston Strategics Corporation] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Clinical Applications of Stem Cells (CASC) 2015
February 26-27, 2015
Singapore, Singapore

NEW BIT’s 8th Annual World Cancer Congress (WCC-2015)
May 15-17, 2015
Beijing, China

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

NEW Assistant or Associate Professor – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

NEW Research Associate – Cancer, Stem Cells, and Immunity Focusing on Membrane Proteins and Signaling Pathways (UT Southwestern Medical Center)

Postdoctoral Positions – Hematopoietic and Induced Pluripotent Stem Cells (Indiana University School of Medicine)

Postdoctoral Fellowship – Cancer Biology (University of California – San Francisco)

Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania School of Medicine)

Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Postdoctoral Research Fellow – Molecular Mechanisms Regulating Transformation and Maintenance of Leukemia Stem Cells (City of Hope)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us